Cargando…

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Immunotherapy has prompted a dramatic change in the management of head and neck squamous cell carcinoma (HNSCC), but the percentage of patients benefiting from treatment is limited to 20% or less. The application of precision oncology to HNSCC introduces the potential for the emergen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burcher, Kimberly M., Lantz, Jeffrey W., Gavrila, Elena, Abreu, Arianne, Burcher, Jack T., Faucheux, Andrew T., Xie, Amy, Jackson, Clayton, Song, Alexander H., Hughes, Ryan T., Lycan, Thomas, Bunch, Paul M., Furdui, Cristina M., Topaloglu, Umit, D’Agostino, Ralph B., Zhang, Wei, Porosnicu, Mercedes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616373/ https://www.ncbi.nlm.nih.gov/pubmed/34830888 http://dx.doi.org/10.3390/cancers13225733

Ejemplares similares

Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC
por: Burcher, Kimberly M., et al.
Publicado: (2021)

In Reply: TP53 Alteration Status and Tumor Mutational Burden Score: Prevalence and Prognosis in Head and Neck Squamous Cell Carcinoma
por: Burcher, Kimberly M, et al.
Publicado: (2022)

A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers
por: Burcher, Kimberly M., et al.
Publicado: (2022)

Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature
por: Bloomer, Chance H., et al.
Publicado: (2023)

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
por: Hughes, Ryan T, et al.
Publicado: (2023)

Serendipitous synergism – an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature
por: Khoury, Lara M., et al.
Publicado: (2022)

A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry
por: Faucheux, Andrew, et al.
Publicado: (2023)

The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma
por: Wilson, Harper L., et al.
Publicado: (2020)

Risk Factors for Opioid Use Disorders in Adult Postsurgical Patients
por: Burcher, Kimberly M, et al.
Publicado: (2018)

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status
por: Porosnicu, Mercedes, et al.
Publicado: (2022)

Régime Assurance Maladie du CERN
por: Burcher, Nadine, et al.
Publicado: (2011)

Régime Assurance Maladie du CERN
por: Burcher, Nadine, et al.
Publicado: (2009)

Régime Assurance Maladie du CERN
por: Burcher, Nadine, et al.
Publicado: (2007)

Gene expression of muscarinic, tachykinin, and purinergic receptors in porcine bladder: comparison with cultured cells
por: Bahadory, Forough, et al.
Publicado: (2013)

Unexplained persistent postpartum palpitations and tachycardia due to Group A Streptococcus
por: Keller, Nathan A., et al.
Publicado: (2015)

Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds
por: Choudhary, Neeraj, et al.
Publicado: (2023)

L'assurance déépendance
por: Vitasse, Michel, et al.
Publicado: (1997)

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy
por: Smith, Margaret R., et al.
Publicado: (2023)

Anticancer Potential of Apigenin and Isovitexin with Focus on Oncogenic Metabolism in Cancer Stem Cells
por: Ghanbari-Movahed, Maryam, et al.
Publicado: (2023)

Inflammation and psychopathology in children following PICU admission: an exploratory study
por: Caspani, Giorgia, et al.
Publicado: (2018)

Porcine Bladder Urothelial, Myofibroblast, and Detrusor Muscle Cells: Characterization and ATP Release
por: Cheng, Ying, et al.
Publicado: (2011)

ATP during Early Bladder Stretch Is Important for Urgency in Detrusor Overactivity Patients
por: Cheng, Y., et al.
Publicado: (2014)

Immunocytochemical characterisation of cultures of human bladder mucosal cells
por: Woodman, Jacqueline R, et al.
Publicado: (2011)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
por: Liu, Liang, et al.
Publicado: (2020)

Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
por: Pal, Dilipkumar, et al.
Publicado: (2023)

P34.05 Three Birds, One Stone: IVIG Use in Hypogammaglobulinemia, Checkpoint Inhibitor Pneumonitis, and Persistent COVID-19
por: Olson, E., et al.
Publicado: (2021)

A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab
por: Bloomer, Chance H., et al.
Publicado: (2022)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

Naringin–Dextrin Nanocomposite Abates Diethylnitrosamine/Acetylaminofluorene-Induced Lung Carcinogenesis by Modulating Oxidative Stress, Inflammation, Apoptosis, and Cell Proliferation
por: Mohamed, Eman E., et al.
Publicado: (2023)

Use of comprehensive genomic profiling for biomarker discovery for the management of non-small cell lung cancer brain metastases
por: Abdulhaleem, Mohammed, et al.
Publicado: (2023)

In the Pursuit of Privacy: The Promises and Predicaments of Federated Learning in Healthcare
por: Topaloglu, Mustafa Y., et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV
por: Hughes, Michael S, et al.
Publicado: (2020)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
por: Rolfes, Verena, et al.
Publicado: (2018)

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
por: Yang, Meng, et al.
Publicado: (2017)

A multivariate modeling framework to quantify immune checkpoint context-dependent stimulation on T cells
por: Karpf, Léa, et al.
Publicado: (2022)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gvqj33qkgrn2i3ebtpdovrn837